Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals

The therapeutic landscape for Friedreich’s ataxia (FRDA) has long been defined by supportive care rather than disease-modifying interventions. The emergence of omaveloxolone—a nuclear factor erythroid 2–related factor 2 (Nrf2) activator—has shifted that narrative, particularly following the MOXIe trial. What’s unclear, however, is how these outcomes translate into routine clinical practice.

A real-world observational study published in the Journal of Neurology offers an early but meaningful glimpse into this question.

A Cohort that Reflects Clinical Reality
This study evaluated 20 adult patients with genetically confirmed FRDA in a single-center, prospective design. The mean age of the cohort was about 40 years with a mean disease duration of about 25 years, reflecting a population clinicians are increasingly encountering as survival improves. Patients received omaveloxolone 150 mg daily and were followed over approximately 24 weeks with structured neurological assessments (mFARS, SARA, FA-ADL) and extensive laboratory monitoring.

Trial populations often skew younger with lower baseline disability; here, patients had a mean mFARS near 60, suggesting more advanced disease. The question, then, is not just about efficacy, but also whether stabilization is a meaningful outcome.

Stability over Progression
Across all major clinical scales, the study found no statistically significant improvement—but importantly, it didn’t find deterioration either. In FRDA, where natural history data suggest steady annual decline (approximately 2–2.2 mFARS points in adults), stability itself may indicate therapeutic effect.

Patients also reported subjective benefits, particularly in fatigue and speech, though these were patient-reported observations and were not reflected in the structured clinical scales used in the study. This type of disconnect isn’t uncommon in neurodegenerative disease and raises practical considerations for how clinicians assess response.

A notable biomarker signal emerged: interleukin-6 (IL-6) levels declined significantly over time (p < 0.0001). While exploratory, this finding may represent a biological signal of interest.

Safety Profile: Consistent, but Not Silent
Safety outcomes aligned closely with prior trial data. No discontinuations occurred over 24 weeks, and no serious adverse events were reported. However, transient elevations in liver transaminases were common—occurring in approximately 50% of patients. These were asymptomatic and reversible, including one case requiring temporary drug interruption.

From a clinical standpoint, this reinforces the need for:

• Routine liver function monitoring, particularly early in therapy
• Awareness that transient elevations are expected and often manageable
• Clear thresholds for interruption (e.g., transaminases >5× ULN, or >3x ULN with evidence of liver dysfunction such as elevated bilirubin)

Cardiac biomarkers, including NT-proBNP, and lipid profiles remained stable, although ongoing monitoring remains essential given known risks of BNP elevation and lipid abnormalities.

Who Benefits?
One of the more challenging findings was the absence of identifiable predictors of response. Neither clinical characteristics nor laboratory markers consistently distinguished responders from non-responders in multivariate analysis.

This underscores a broader issue in FRDA therapeutics: the authors suggest that omaveloxolone’s effect may depend on residual neuronal function, raising the possibility that earlier intervention could yield greater measurable benefit.

Translating Evidence into Practice
For clinicians caring for patients with FRDA, several practical insights emerge. Stabilization can be considered a meaningful therapeutic success, particularly in patients with more advanced disease where halting progression may preserve function and quality of life. Monitoring should extend beyond observable symptoms, with biomarkers such as IL-6 offering potential early signals of biological effect. And setting realistic expectations is key; functional improvements may be subtle or delayed.

Perhaps most importantly, this study highlights a shift from efficacy under ideal conditions to effectiveness in real-world populations, including one that’s older, more heterogeneous, and often underrepresented in trials.

The data remain preliminary, limited by small sample size and short follow-up. Yet they point in a consistent direction: omaveloxolone appears to be slowing disease trajectory. For individuals with FRDA, that may be clinically transformative.

Reference
Lima SM, Caltagirone M, Messina C, Quartetti U, Rini N, D’Amico F, Brighina F, Di Stefano V. Early experience on omaveloxolone in adult patients with Friedreich’s ataxia: a real-world observational study. J Neurol. 2025;272:742. doi:10.1007/s00415-025-13487-1